PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation

Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53- Deficient Prostate Cancer to Radiation

(2017) Anne L. van de Ven et al.   MOLECULAR CANCER THERAPEUTICS

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

Does radiotherapy still have a role in unresected biliary tract cancer?

(2016) Erqi L. Pollom et al.   Cancer Medicine

Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies

(2015) N. Schweitzer et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic spectra of biliary tract cancer

(2015) Hiromi Nakamura et al.   NATURE GENETICS

Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells

(2015) Caroline V.M. Verhagen et al.   RADIOTHERAPY AND ONCOLOGY

Ovarian cancer standard of care: are there real alternatives?

(2015) Chiara Della Pepa et al.   Chinese Journal of Cancer

Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer

(2014) Felix Y. Feng et al.   BREAST CANCER RESEARCH AND TREATMENT

Transforming growth factor-β1-induced epithelial–mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma

(2014) Ze-Yu Shuang et al.   CANCER LETTERS

Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells

(2014) Annika Kötter et al.   Molecular Oncology

New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing

(2014) J. S. Ross et al.   ONCOLOGIST

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

(2014) Chaitanya R. Churi et al.   PLoS One

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

(2013) S. K. Sandhu et al.   ANNALS OF ONCOLOGY

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

(2013) Nigel Bundred et al.   INVESTIGATIONAL NEW DRUGS

Incidence and mortality trends for biliary tract cancers in Austria

(2013) Matthias Pinter et al.   LIVER INTERNATIONAL

Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update

(2012) Shahid A Khan et al.   GUT

The Clinical Development of Molecularly Targeted Agents in Combination With Radiation Therapy: A Pharmaceutical Perspective

(2012) Ozlem U. Ataman et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma

(2011) Yu-Jie Hou et al.   LABORATORY INVESTIGATION

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft

(2011) J. M. Senra et al.   MOLECULAR CANCER THERAPEUTICS

Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective

(2010) Marcel Verheij et al.   DRUG RESISTANCE UPDATES

Trends in the incidence and management of biliary tract cancer: A French population-based study

(2010) Côme Lepage et al.   JOURNAL OF HEPATOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Sensitization to Radiation and Alkylating Agents by Inhibitors of Poly(ADP-ribose) Polymerase Is Enhanced in Cells Deficient in DNA Double-Strand Break Repair

(2010) D. A. Loser et al.   MOLECULAR CANCER THERAPEUTICS

Resection of Hilar Cholangiocarcinoma

(2009) Fumito Ito et al.   ANNALS OF SURGERY

PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications

(2009) Yvette Drew et al.   DRUG RESISTANCE UPDATES

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA repair deficiency as a therapeutic target in cancer

(2008) Sarah A Martin et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT